Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals

The association between COVID-19 symptoms and antibody responses against SARS-CoV-2 is poorly characterized. We analyzed antibody levels in individuals with known SARS-CoV-2 infection to identify potential antibody-symptom associations. Convalescent plasma from 216 SARS-CoV-2 RNA+ individuals with symptomatology information were tested for the presence of IgG to the spike S1 subunit (Euroimmun ELISA), IgG to receptor binding domain (RBD, CoronaCHEK rapid test), and for IgG, IgA, and IgM to nucleocapsid (N, Bio-Rad ELISA). Logistic regression was used to estimate the odds of having a COVID-19 symptom from the antibody response, adjusting for sex and age. Cough strongly associated with antibodies against S1 (adjusted odds ratio [aOR]= 5.33; 95% CI from 1.51 to 18.86) and RBD (aOR=4.36; CI 1.49, 12.78). In contrast, sore throat significantly associated with the absence of antibodies to S1 and N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91). Similarly, lack of symptoms associated with the absence of antibodies to N and RBD (aOR=0.16; CI 0.03, 0.97 and aOR=0.16; CI 0.03, 1.01). Cough appeared to be correlated with a seropositive result, suggesting that SARS-CoV-2 infected individuals exhibiting lower respiratory symptoms generate a robust antibody response. Conversely, those without symptoms or limited to a sore throat while infected with SARS-CoV-2 were likely to lack a detectable antibody response. These findings strongly support the notion that severity of infection correlates with robust antibody response.

74 from SARS-CoV-2 infection were tested for the presence of IgG antibodies to spike (S1), IgG 75 antibodies to the receptor binding domain (RBD), and total antibodies to nucleocapsid (N).

79
This study used stored samples and data from studies that were approved by The Johns 80 Hopkins University School of Medicine Institutional Review Board. All study participants 81 provided written informed consent and were de-identified prior to laboratory testing.

82
To assess the antibody levels of SARS-CoV-2 infected individuals, samples from 216 83 participants from the Baltimore/Washington DC area who were screened to donate COVID-19 84 convalescent plasma (CCP) and had accompanying symptom data from April 2020-January 2021 85 were evaluated. 5,12,13 All were at least 18 years old and met the eligibility criteria for blood 86  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 10, 2022. ; 119 were considered to be confounding variables and therefore included in adjusted models. 5 120 Adjusted odds ratios with a p<0.05 were considered significant. All analysis were performed in 121 STATA v.14.2 (College Station, TX  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

185
To further investigate the seronegativity of individuals reporting sore throat, individuals were 186 grouped into three categories: whether they reported no symptoms, reported symptoms other 187 than sore throat, or reported sore throat. Individuals who reported a sore throat and cough as co-188 symptoms were placed in the second category. Among the analytes with ≥80% overall 189 detectability, the median cytokine levels were not significantly higher among convalescent 190 individuals who were symptomatic, asymptomatic, or reporting sore throat (Fig 4). Among the 191 analytes with <80% overall detectability, the percent detectability analytes in individuals 192 reporting sore throat (no cough) versus other symptoms were not significantly different (Fig 5). This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 10, 2022. ; 220 virus in these convalescent individuals, thus not necessitating a robust antibody response; 221 however, our cytokine and chemokine data do not support this rationalization. Given that a 222 median of 30 days had passed since symptom resolution in this subject pool at the time of blood 223 collection, it is possible that cytokine and chemokine levels may have declined to their basal 224 levels. 25

225
Our study had several limitations. First, capture of clinical symptoms was based on self-226 reporting rather than review of the patients' medical records. Individuals reporting a certain 227 symptom may have experienced a more severe presentation than others reporting the same 228 symptom, which was not captured by this dataset and may have influenced antibody production. Acknowledgments The authors would like to thank the participants who donated their 242 plasma and the study trial staff, without whom this investigation could not be conducted.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.